Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1093/ndt/gfx188 http://scihub22266oqcxt.onion/10.1093/ndt/gfx188 C5888998!5888998 !28992127     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 300.79999999999995 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 300.79999999999995 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 300.79999999999995 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\28992127 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Nephrol+Dial+Transplant 2018 ; 33 (4 ): 645-652 Nephropedia Template TP {{tp|p=28992127 |t=2018. Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial |pdf=|usr=}}{{28992127 }} gab.com Text Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients Application of the PROPKD score in the TEMPO trial JO: Nephrol Dial Transplant http://www.kidney.de/pget.php?&tw=1&pmid=28992127 #FOAvip BACKGROUND: The PROPKD score has been proposed to stratify the risk of progression to end-stage renal disease in autosomal dominant polycystic kidney disease (ADPKD) subjects. We aimed to assess its prognostic value in a genotyped subgroup of subjects from the Tolvaptan Phase 3 Efficacy and Safety Study in Autosomal Dominant Polycystic Kidney Disease (TEMPO3/4) trial. METHODS: In the post hoc analysis, PKD1 and PKD2 were screened in 770 subjects and the PROPKD score was calculated in mutation-positive subjects (male: 1 point; hypertension <35?years: 2 points; first urologic event <35?years: 2 points; nontruncating PKD1 mutation: 2 points; truncating PKD1 mutation: 4 points). Subjects were classified into low-risk (LR; 0-3 points), intermediate-risk (IR; 4-6 points) and high-risk (HR; 7-9 points) groups. RESULTS: The PROPKD score was calculated in 749 subjects (LR?=?132, IR?=?344 and HR?=?273); age was inversely related to risk (LR?=?43.6?years, IR?=?39.5?years, HR?=?36.2?years; P?<?0.001). Subjects from the HR group had significantly higher height-adjusted total kidney volume (TKV) and rates of TKV growth. While baseline renal function was similar across all risk groups, the rate of estimated glomerular filtration rate (eGFR) decline significantly increased from LR to HR in the placebo group. Tolvaptan treatment effectiveness to reduce TKV growth was similar in all three risk categories. While tolvaptan significantly slowed eGFR decline in the IR (tolvaptan?=?-2.34 versus placebo?=?-3.33?mL/min/1.73?m2/year; P?=?0.008) and HR groups (tolvaptan?=?-2.74 versus placebo?=?-3.94?mL/min/1.73 m2/year; P?=?0.002), there was no difference in the LR group (tolvaptan?=?-2.35 versus placebo?=?-2.50?mL/min/1.73 m2/year; P?=?0.72). Excluding the LR subjects from the analysis improved the apparent treatment effect of tolvaptan on eGFR decline. CONCLUSION: This study confirms the prognostic value of the PROPKD score and suggests that it could reduce costs and enhance endpoint sensitivity by enriching future study populations for rapidly progressing ADPKD subjects. Twit Text FOAVip Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients Application of the PROPKD score in the TEMPO trial ????Nephrol Dial Transplant http://www.kidney.de/pget.php?&tw=1&pmid=28992127 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28992127 #FOAvip English Wikipedia <ref>{{Cite pmid|28992127 }}</ref> Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial #MMPMID28992127 Cornec-Le Gall E ; Blais JD ; Irazabal MV ; Devuyst O ; Gansevoort RT ; Perrone RD ; Chapman AB ; Czerwiec FS ; Ouyang J ; Heyer CM ; Senum SR ; Le Meur Y ; Torres VE ; Harris PC Nephrol Dial Transplant 2018[Apr]; 33 (4 ): 645-652 PMID28992127 show ga BACKGROUND: The PROPKD score has been proposed to stratify the risk of progression to end-stage renal disease in autosomal dominant polycystic kidney disease (ADPKD) subjects. We aimed to assess its prognostic value in a genotyped subgroup of subjects from the Tolvaptan Phase 3 Efficacy and Safety Study in Autosomal Dominant Polycystic Kidney Disease (TEMPO3/4) trial. METHODS: In the post hoc analysis, PKD1 and PKD2 were screened in 770 subjects and the PROPKD score was calculated in mutation-positive subjects (male: 1 point; hypertension <35?years: 2 points; first urologic event <35?years: 2 points; nontruncating PKD1 mutation: 2 points; truncating PKD1 mutation: 4 points). Subjects were classified into low-risk (LR; 0-3 points), intermediate-risk (IR; 4-6 points) and high-risk (HR; 7-9 points) groups. RESULTS: The PROPKD score was calculated in 749 subjects (LR?=?132, IR?=?344 and HR?=?273); age was inversely related to risk (LR?=?43.6?years, IR?=?39.5?years, HR?=?36.2?years; P? |*Severity of Illness Index [MESH] |Adolescent [MESH] |Adult [MESH] |Age Factors [MESH] |Antidiuretic Hormone Receptor Antagonists/therapeutic use [MESH] |Clinical Trials as Topic [MESH] |Disease Progression [MESH] |Female [MESH] |Gene Rearrangement [MESH] |Glomerular Filtration Rate/*drug effects [MESH] |Humans [MESH] |Hypertension/*physiopathology [MESH] |Kidney/*physiopathology [MESH] |Male [MESH] |Middle Aged [MESH] |Polycystic Kidney, Autosomal Dominant/drug therapy/genetics/*pathology [MESH] |Predictive Value of Tests [MESH] |Prospective Studies [MESH] |Research Design [MESH] |Risk Assessment/*methods [MESH] |Risk Factors [MESH] |TRPP Cation Channels/genetics [MESH] |Tolvaptan/*therapeutic use [MESH]Can we further enrich autosomal dominant polycystic kidney disease cli(epmc).pdf DeepDyve Pubget Overpricing